Clinically, pretreatment with G-CSF (as in the FLAG regimen, which is a combination therapy of fludarabine, cytarabine, and G-CSF), seems to be effective and well tolerated in the treatment of poor-risk AML patients (Montillo et al, 1998; Jackson et al, 2001). This evidence concerns the gene CSF3 and acute myeloid leukemia.